Cord Blood Plasma and Alpha-Fetoprotein (AFP): An Honest Look at the Research

What are cord blood plasma and AFP?

Cord blood plasma is the liquid portion of blood collected from the umbilical cord and placenta after a healthy birth, once the cellular components are separated out. Because it comes from the very start of life, researchers have long been interested in the mix of proteins, growth factors, and signaling molecules it contains — substances the body uses to grow, repair, and regulate itself.

Alpha-fetoprotein, usually shortened to AFP, is one specific protein found at high levels in the developing fetus and in cord blood. In adults it is normally present only in trace amounts, which is part of why it draws scientific attention: it is a molecule strongly associated with early development that largely disappears later in life. AFP can be studied as part of whole cord blood plasma or considered as an isolated factor in its own right.

How they are thought to work

The proposed mechanisms here sit firmly in the realm of research, so it helps to be precise about what is hypothesis versus what is established. For AFP, a 2022 review in Trends in Immunology describes the protein as an immunomodulator — meaning it appears to influence and regulate immune cell populations rather than simply stimulating or suppressing immunity across the board. This regulatory quality is the central reason AFP is being explored.

For cord blood plasma more broadly, the thinking borrows from the wider field of young plasma research. The idea is that circulating factors present early in life may carry signals that support tissue and cellular function, and that reintroducing such factors could influence age-related changes. It is important to stress that this is a working rationale drawn largely from animal models, not a confirmed mechanism in humans.

What the research actually shows

Being honest about the evidence tier matters most here. The strongest concrete data on the young plasma concept comes from preclinical work: a 2014 study in Nature Medicine using parabiosis — surgically joining the circulatory systems of young and old mice — reported that exposure to young blood reversed certain age-related cognitive impairments in the older animals. This is compelling as a rationale, but it is an animal study, and the human evidence behind these approaches remains very limited.

On AFP specifically, the available literature is review-level and conceptual rather than built on large clinical trials. The 2022 Trends in Immunology review summarizes AFP's immune-regulating activity, and a 2018 review in Therapeutic Delivery frames potential applications in autoimmune disease and cancer while explicitly noting that the evidence is early. In other words, the scientific interest is real and the mechanisms are plausible, but we do not have robust human outcome data demonstrating proven benefit. No one should read this as established therapy.

What it is being explored for

Given the research above, the areas of exploration follow logically. AFP's immunomodulatory profile has led reviewers to discuss it in the context of autoimmune conditions — where dialing immune activity toward balance, rather than blunt suppression, is the goal — and, separately, in oncology research. These are framed as possibilities under investigation, not as available treatments.

Cord blood plasma sits within the broader longevity and healthy-aging conversation, driven by the young-plasma hypothesis. People drawn to this space are typically interested in age-related decline and cellular signaling. The candid framing is this: these are investigational approaches that are not approved as standard therapies in all jurisdictions, and the human data has not caught up with the early laboratory and animal findings. Anyone considering them deserves a clear-eyed picture of where the science genuinely stands.

How Strong Craft Regen approaches this

Strong Craft Regen is a coordination and education service, not a clinic and not a substitute for medical advice. Our role is to help you understand emerging areas like cord blood plasma and AFP honestly — including, as in this case, where the evidence is still early or limited to animal studies — and to coordinate care with the licensed physicians at Innovita Clinic in Vilnius, Lithuania.

Any decision about whether something like this is appropriate is a medical one, made with a qualified physician who can weigh your individual situation, the current state of the evidence, and the regulatory status of these investigational approaches. If you would like to learn more or talk through whether a physician consultation makes sense for you, you are welcome to book a call with us. We will keep the conversation grounded and pressure-free.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Cord Blood Plasma & AFP is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.